Pure Global AI
NCT06394674Recruiting

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

A Prospective, Randomized, Phase ll Clinical Trial of Single-agent Treatment With Different Doses of Sulfamethoxazole Furmonertinib in Patients With Advanced, Metastatic Lung Adenocarcinoma Who Have Progressed After First- or Second-line Treatment With EGFR-TKl Osimertinib
Changhai HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
Furmonertinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Changhai Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Sep 01, 2026
Enrollment
84 participants
Primary outcome

Objective Response Rate(ORR)

Summary

This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84
 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line
 treatment with Osmertinib, who were randomly assigned to trial group 1 and trial group 2, and
 were given Furmonertinib 160 mg and 240 mg once/day, orally, respectively, with efficacy
 evaluated every 6 weeks until disease progression, intolerable toxic side effects, or
 Subjects voluntarily withdrew informed consent.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06394674
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06394674 through Pure Global AI's free database. This Phase 2 trial is sponsored by Changhai Hospital and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 84 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.